万基遗传 MYGN 深 沪
等待开盘 05-21 09:30:00 美东时间
3.705
+0.155
+4.37%
华盛通- 最 高3.73
- 今 开3.55
- 成交量 78.09万股
- 最 低 3.535
- 昨 收 3.55
- 总市值 34.99万
- 52周最高 8.59
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 3.53
- 委 比 -34.70%
- 总股本 9.44万
- 历史最高 50.44
- 量 比 0.68
- 振 幅 5.49%
- 历史最低 3.53
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Netflix actress Jackie Tohn partners with Myriad Genetics to raise awareness about hereditary cancer testing. After discovering she carried a BRCA1 gene variant following her father's cancer diagnosis, Tohn underwent a prophylactic double mastectomy and plans for an oophorectomy. She emphasizes the importance of genetic testing, especially for those with a family history of cancer. Myriad's MyRisk® Hereditary Cancer Test evaluates 63 genes to ass...
05-15 15:00
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, a leader in molecular diagnostics, announced that its management will participate in two healthcare conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The Goldman Sachs presentation will be available via live audio webcast on Myriad’s investor website. Myriad Genetics specializes in molecular tests that provide genetic insi...
05-07 20:05
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Myriad Genetics shares are trading lower after the company reported worse-than-expected Q1 financial results.
Myriad Genetics shares are trading lower after the company reported worse-than-...
05-06 04:52
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
万基遗传将于5月5日盘后发布财报 近期股价震荡振幅超10%
经济观察网 万基遗传近期市场关注集中于即将发布的季度财报及股价波动情况，将于美东时间5月5日盘后披露业绩。 业绩经营情况： 公司将于美东时间2026年05月0...
05-04 23:54
Myriad Genetics Receives Japan Approval For MyChoice Test For Prostate Cancer Patients
Myriad Genetics Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice®
04-14 21:18
Myriad Genetics Gets FDA Approval Of MyChoice CDx Test As Companion Diagnostic For Zejula, PARP Inhibitor From GSK, For Patients With Advanced Ovarian Cancer
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the
03-18 04:12
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
<p>Myriad Genetics announced the FDA approval of its MyChoice CDx Test as a companion diagnostic for GSK's Zejula, a PARP inhibitor for advanced ovarian cancer patients. This approval establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S. The test identifies HRD-positive patients using next-generation sequencing to assess BRCA1/2 genes and tumor genomic instability, helping guide precise treatment decisions....
03-17 20:05
